Business Wire

Tallence Selects Radisys’ Engage Platform as Foundation for New Cloud Messaging Solution

16.12.2020 16:00:00 EET | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today announced that Tallence AG, a digital transformation technology and management consultancy, has selected Radisys’ Engage Media Server as the foundation for a new voice messaging system for a Tier 1 European operator. Tallence will leverage the extensive capabilities of the Engage Media Server, a foundational element of the Radisys Engage communications services enablement platform, to create enhanced digital customer experiences with high quality interactions and augment content to create greater customer satisfaction and increase customer loyalty.

Highlights

  • Digital communications solutions continue to become more integrated into both mobile and web paths of the customer journey. The COVID-19 pandemic is accelerating the shift in customer experience to online solutions. Application developers and Communication Service Providers (CSPs) must be able to quickly bring online new, scalable and elastic services that can be adapted to changing market conditions. With the right platform, they can meet the combined challenges of rapid increases and fluctuations in customer access traffic and increasingly remote, distributed workforces, all while enabling a top quality seamless experience.
  • Traditionally, only large enterprises had the infrastructure and budgets to deliver compelling digital experiences that seamlessly tie voice and video interaction with content and business processes. By migrating these services to the cloud on the foundation of Radisys’ Engage Media Server, Tallence is providing services that enable businesses of all sizes to reach their consumers at lower cost, with greater flexibility, and optimal use of resources.
  • Radisys’ Engage Media Server delivers a rich set of media capabilities for developers and CSPs to create enhanced and engaging digital customer experiences. It provides the foundation for high-value voice and video features to enrich digital experience applications, and it enables CSPs to leverage the cloud for low cost and increased efficiency with industry-leading capacities for best total cost of ownership. The cloud-based Engage Media Server delivers:
    • On demand scalability which reduces costs for broad market reach for digital experience applications and services at attractive price points.
    • Optimal user experiences that tie to brand and customer satisfaction by using high quality voice and video, including real-time processing for 4G and 5G, PSTN, and web or mobile app modalities that can adapt to various bandwidth and network conditions and ensure CSPs can meet even the most rigorous availability and quality service level agreements with their customers.
    • Powerful tools for application developers to quickly bring to market applications and services and on-demand adaptation for new campaigns through industry-leading analytics.

“Radisys’ Engage Media Server delivers the scalability and capabilities required for exceptional digital experience-related services for our new cloud-based voice messaging solution deployed for our tier-one customer,” said Christian Schöntag, Head of Consulting, Tallence AG. “Furthermore, Radisys’ extensive experience in cloud-based media processing is critical for enabling us to ensure reliability and scalability for our customers as they accelerate their move to the cloud.”

“Tallence AG has an impressive reputation in delivering innovative customer experiences that can provide compelling ROIs for their customers and sticky, loyalty building experiences for their end users,” said Al Balasco, Radisys’ Head of Media, Core and Applications Business. “Our Engage platform is deployed by over 150 operators and currently serves 2 billion users worldwide. Tallence’s cloud-based application builds on this mobile network-optimized platform to deliver services for a new age and represents the value of our media server to leading solution providers in enabling digital consumer experiences and e-commerce services.”

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

About Tallence

Tallence AG is a technology and management consultancy for digital transformation. We support our customers in using digitalization to their advantage and creating competitive advantages. We advise, develop and manage with a hands-on and result-oriented approach. Whether international technology group, traditional medium-sized enterprises or public sector: The benefit for the end customer is always the guiding principle and driving force behind Tallence. We ensure this through genuine expert performance and the highest level of commitment. Our clients come from diverse industries including telecommunications, information, media and energy. At Tallence AG more than 150 IT developers, machine learning specialists and management consultants based in our German office locations in Hamburg, Frankfurt, Marburg, Görlitz and Karlsruhe are working on future-oriented topics of the Digital Economy. Read more on: www.tallence.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye